Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...
Pfizer says COVID vaccine protection lasts at least 6 months; Company can now seek full FDA approval
The ongoing Phase 3 clinical trial of Pfizer/BioNTech's coronavirus vaccine confirms its protection lasts at least six months after the second dose, the companies said Thursday. The companies can now ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (PFE) (NYSE: PFE, “Pfizer”) and BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results